Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM).

Thomas, Sheeba K.; Melendez, Andre G.; Feng, Lei; Wang, Michael; Neelapu, Sattva S.; Shah, Jatin J.; Orłowski, Robert Z.; Weber, Donna M.

doi:10.1200/jco.2014.32.15_suppl.8536

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phase 1 trial of single agent pomalidomide, a third generation IMID administered days 1-28 continuously in relapsed and/or refractory WM patients, determined the maximum tolerated dose to be 1 mg/day. However, a day 1-21 schedule with a 7-day break warrants evaluation, as it may be better tolerated and could allow recovery of cytopenias [120]. A phase I dose-escalating trial of pomalidomide in combination with rituximab and dexamethasone enrolled 7 patients before it was closed for therapy associated IgM flare with symptomatic hyperviscosity, requiring emergent plasmapheresis in 3 patients (43%), all of whom had a baseline IgM of N4000 [121].…”

Section: Is There a Role For Stem Cell Transplantation In The Currentmentioning

confidence: 99%

Waldenström macroglobulinemia: What a hematologist needs to know

et al. 2015

View full text Add to dashboard Cite

Section: Is There a Role For Stem Cell Transplantation In The Currentmentioning

confidence: 99%

Waldenström macroglobulinemia: What a hematologist needs to know

et al. 2015

View full text Add to dashboard Cite

“…A Phase I study of single-agent oral pomalidomide in R/R WM showed an MTD of 1 mg/day, with CTC grade ‡3 toxicities, including syncope (11%), dizziness (11%), neutropenia (33%) and infection (11%) [41]. At a median follow-up of 30 months, eight patients remained alive and one continued to receive therapy.…”

Section: Immunomodulatorsmentioning

confidence: 99%

Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

Chakraborty

Kapoor

Ansell

et al. 2015

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Lymphoplasmacytic lymphoma is an indolent B-cell, non-Hodgkin lymphoma (NHL), the majority of which are characterized by production of a monoclonal immunoglobulin M (IgM) protein and are known as Waldenström macroglobulinemia. Identification of highly recurrent activating somatic mutation in MYD88 has improved our understanding of the pathogenesis of Waldenström macroglobulinemia and has therapeutic implications. Here, we review novel therapeutic agents in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, which have emerged in the past decade and discuss their comparative efficacy and safety, with emphasis on a Bruton's tyrosine kinase (BTK) inhibitor, which has been recently approved by the US FDA, specifically for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Future research should focus on identifying targeted agents against activating mutations and long-term data for currently available novel agents should be critically evaluated, both in treatment-naïve and in relapsed/refractory settings.

show abstract

“…A newer generation immunomodulator pomalidomide has been tested in a Phase I study in WM. Grade 3 or higher adverse effects included syncope, dizziness, neutropenia and infection ( Table 2) [39]. A study on 12 previously treated WM patients using a non-myelosuppressive regimen, clarithromycin, low-dose thalidomide and dexamethasone showed a response in 83% of patients [40].…”

Section: Immunomodulatory Drugsmentioning

confidence: 99%